ICD-116C00	ENURESIS Enuresis
ICD-10F98.0	Nonorganic enuresis
DSM-5-TRF98.0	Enuresis

1. Definition and nosology

Enuresis (ICD-11: 6C00; DSM-5-TR: F98.0) — involuntary urination persisting when the child's developmental age reaches at least 5 years. Frequency: at least twice a week for ≥ 3 months or significant functional impairment.

Subtypes (ICCS — International Children's Continence Society 2014):

• Monosymptomatic nocturnal enuresis — only nocturnal, no daytime symptoms;
• Non-monosymptomatic enuresis — daytime symptoms (urgency, increased frequency, incontinence) additional;
• Primary — child has never achieved 6 months of sustained dryness;
• Secondary — relapse after a dry period.

2. History

• In the 19th century, familial clustering of enuresis began to be noted in the clinical literature.
• Mowrer O.H. (1938) — invented the pad-and-bell alarm.
• ICCS (1989) — international standardization.
• NICE CG111 (2010) — nocturnal enuresis clinical guideline.

3. Epidemiology

• Prevalence: Age 5: 15–20%, Age 7: 5–10%, Age 10: 3–5%, Adults: 1–2%.
• Sex: male 2:1.
• Spontaneous remission occurs in approximately 15% per year.
• Comorbidity: ADHD ~30%, anxiety, conduct disorders, constipation.

4. Aetiology and pathogenesis

• Heritability 70% (Bayoumi R.A. reviews).
• Monosymptomatic nocturnal
  • Immaturity of nocturnal vasopressin (ADH) secretion (nocturnal polyuria);
  • Elevation of arousal threshold;
  • Bladder capacity below age norm.
• Non-monosymptomatic form — bladder overactivity, constipation association.
• Secondary enuresis — stress, urinary infection (UTI), diabetes, psychiatric trigger.

5. Clinical features

• Nocturnal enuresis.
• Daytime symptoms (non-monosymptomatic): urgency, holding maneuvers (Vincent's curtsy, leg crossing), increased frequency, incontinence.
• Social-emotional: shame, decreased self-esteem, avoidance of social activities (camping, sleepovers).

6. Diagnosis

6.1 Unified diagnostic criteria (DSM-5-TR / ICD-11 / ICCS 2014)

A. Repeated urinary incontinence (in bed or clothes), voluntary or involuntary.

B. Frequency: ≥2 times per week, ≥3 months; or significant distress/functional impairment.

C. Developmental age ≥ 5 years.

D. Not fully explained by substance (diuretic) or medical condition (diabetes, UTI, structural anomaly).

Qualifiers: only nocturnal / only diurnal / nocturnal and diurnal; primary / secondary; monosymptomatic / non-monosymptomatic.

6.2 Source-specific clarifications

• ICCS 2014 — subtype terminology standard.
• NICE CG111 — diagnosis and algorithm.
• AAP — pediatric assessment.

6.3 Diagnostic algorithm

1. Clinical interview — onset, frequency, daytime symptoms, family history.
2. Urinalysis and culture — rule out UTI.
3. Voiding diary 3 days — for daytime symptoms.
4. Constipation assessment (Bristol Stool Chart).
5. Medical: weight, glucose, blood pressure.
6. If structural anomaly suspected - urinary USG; uroflowmetry in non-monosymptomatic case.

6.4 Differential diagnosis

7. Examination and assessment

• Urine analysis, culture.
• Voiding and constipation diary.
• Urinary ultrasound (atypical presentation).
• Comorbid ADHD, anxiety screening.

8. Treatment

8.1 General principles (ICCS 2020 · NICE CG111)

1. Behavioral intervention:
   • Conservative recommendations — reducing fluid intake before bedtime, adequate water intake during the day, regular urination, resolving constipation.
   • Positive reinforcement (star chart) — for dry nights.
2. First-line specific intervention:
   • Enuresis alarm — pad-and-bell; ≥ 6 years old, if motivated; long-term good outcome; about 50% achieve 14 consecutive dry nights and about 40% remain dry at follow-up (low-quality evidence). Evidence: Caldwell P.H. Cochrane 2020.
   • Desmopressin — synthetic ADH analog; rapid effect, but high relapse upon discontinuation. ≥ 6–7 years.
3. Second-line:
   • Alarm + desmopressin combination;
   • Anticholinergic (oxybutynin) — in the context of non-monosymptomatic overactive bladder.
4. Refractory: imipramine (TCA) — cardiac monitoring; use cautiously, overdose toxicity.
5. Resolving constipation — PEG (polyethylene glycol) first-line; in non-monosymptomatic or comorbid encopresis context.

8.2 Source-specific clarifications

• ICCS 2020 — alarm and desmopressin first-line; “wait and see” until age 5, then active intervention.
• NICE CG111 — same algorithm.
• AAP — pediatric recommendations.

Treatment methods

1. Enuresis Alarm — Mowrer — Bed alarm or clothing alarm (humidity sensor); ≥ 4 weeks continuous use; typical use 12–16 weeks. Cochrane meta-analysis — most evidence-based long-term method.
2. Desmopressin — Oral 0.2–0.4 mg or sublingual; 1 hour before bedtime; limiting fluids before bedtime is important (risk of hyponatremia).
3. Voiding and Constipation Diary — 3-day; frequency, volume, bladder capacity, daytime symptoms, defecation frequency.
4. Anticholinergic (Oxybutynin) — Against background of over-active bladder; if daytime symptoms are present.
5. PEG (Constipation correction) — First-line; also used in encopresis.

9. Prognosis

• Spontaneous remission occurs in approximately 15% per year; with intervention, remission occurs in most patients.
• Constipation management is important.
• Comorbid ADHD, anxiety — parallel intervention.

10. Myths and misconceptions

Myth 1: “In nocturnal enuresis, electrophoresis to the groin and buttock area stimulates the urinary center”

Why it is widespread: Soviet-era physiotherapy practice; presented as “safe” by family doctors.

Clinical logic: If daytime urine output is normal and the problem did not spontaneously arise after any illness, the problem is not at the kidney/bladder/spinal cord level. Pathogenesis is ADH dysregulation, arousal threshold and bladder capacity — electrophoresis does not affect these.

Evidence: ICCS 2020, NICE CG111 — no international guideline includes electrophoresis. Risk: skin irritation, psychosexual burden.

Real clinical step: Alarm or desmopressin.

Myth 2: “It will just pass on its own, no intervention needed”

Evidence: Spontaneous remission ~15% per year, but untreated persistence creates socio-emotional burden; ICCS 2020 recommends active intervention from age 5+.

Myth 3: “Punishment or insult corrects a child”

Evidence: Punishment is contraindicated; self-esteem reduction, depression risk; positive reinforcement is superior.

Myth 4: “Pre-bedtime water restriction alone is sufficient”

Evidence: Adjunct measure; ineffective alone in most patients; requires specific intervention.

Myth 5: “Imipramine or antidepressants are first-line”

Evidence: imipramine in refractory cases; cardiac side effects and overdose risk; alarm and desmopressin superior.

Myth 6: “Acupuncture and homeopathy cure enuresis”

Evidence: Cochrane reviews — the effect of these complementary interventions has not been proven.

11. Sources

1. WHO. ICD-11. 6C00 Enuresis. 2024.
2. APA. DSM-5-TR. 2022.
3. NICE CG111. Nocturnal enuresis in children and young people under 19. 2010.
4. Nevéus T. et al. Management and treatment of nocturnal enuresis — an updated standardization document from the International Children's Continence Society. J Pediatr Urol 2020;16(1):10–19.
5. Caldwell P.H., Codarini M., Stewart F. et al. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev 2020;(5):CD002911.
6. Bayoumi R.A., Eapen V., Al-Yahyaee S. et al. The genetic basis of inherited primary nocturnal enuresis: a UAE study. J Psychosom Res 2006;61(3):317–320.